Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Open Label, Long-term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients

NCT00105937 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00105937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00105937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Open Label, Long-term Study of OraVescent Fentanyl Citrate for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients
Lead sponsor
Cephalon
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2004
Completion date
November 30, 2006
Enrollment
300
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, pain